# Activation of the transcription factor NRF2 mediates the anti-inflammatory properties of a subset of over-the-counter and prescription NSAIDs

Graphical abstract

Highlights

- A subset of nonsteroidal anti-inflammatory drugs (NSAIDs) activates NRF2

- C151 of the chaperone protein KEAP1 is necessary for NRF2 activation by indomethacin

- Indomethacin reduces inflammation in endotoxemia and gout models dependent on NRF2

Authors

Anna Eisenstein, Brandon K. Hilliard, Scott D. Pope, ..., Hui Tian, Harding H. Luan, Andrew Wang

Correspondence

hluan@ngmbio.com (H.H.L.),
andrew.wang@yale.edu (A.W.)

In brief

The use of nonsteroidal anti-inflammatory drugs (NSAIDs) is ubiquitous. Herein, Eisenstein et. al., identify a noncanonical mechanism of action for the anti-inflammatory activity of NSAIDs through activation of the transcription factor, nuclear factor erythroid 2-related factor 2 (NRF2). In endotoxemia and gout models, indomethacin improved inflammation in an NRF2-dependent manner.

CellPress

Immunity

CellPress

Article

Activation of the transcription factor NRF2 mediates the anti-inflammatory properties of a subset of over-the-counter and prescription NSAIDs

Anna Eisenstein,[1,7] Brandon K. Hilliard,[2,6,7] Scott D. Pope,[3,4] Cuiling Zhang,[2] Pranali Taskar,[5] Daniel A. Waizman,[3] Kavita Israni-Winger,[3] Hui Tian,[5] Harding H. Luan,[5,*] and Andrew Wang[2,8,*]

[1]Department of Dermatology, Yale School of Medicine, New Haven, CT 06520, USA
[2]Department of Internal Medicine and Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA
[3]Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA
[4]Howard Hughes Medical Institute, New Haven, CT, USA
[5]NGM Biopharmaceuticals, South San Francisco, CA 94080, USA
[6]Present address: Medical Scientist Training Program, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
[7]These authors contributed equally
[8]Lead contact
*Correspondence: hluan@ngmbio.com (H.H.L.), andrew.wang@yale.edu (A.W.)
https://doi.org/10.1016/j.immuni.2022.04.015

SUMMARY

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase (COX) enzymes and are ubiquitously used for their anti-inflammatory properties. However, COX inhibition alone fails to explain numerous clinical outcomes of NSAID usage. Screening commonly used NSAIDs in primary human and murine myeloid cells demonstrated that NSAIDs could be differentiated by their ability to induce growth/differentiation factor 15 (GDF15), independent of COX specificity. Using genetic and pharmacologic approaches, NSAID-mediated GDF15 induction was dependent on the activation of nuclear factor erythroid 2-related factor 2 (NRF2) in myeloid cells. Sensing by Cysteine 151 of the NRF2 chaperone, Kelch-like ECH-associated protein 1 (KEAP1) was required for NSAID activation of NRF2 and subsequent anti-inflammatory effects both *in vitro* and *in vivo*. Myeloid-specific deletion of NRF2 abolished NSAID-mediated tissue protection in murine models of gout and endotoxemia. This highlights a noncanonical NRF2-dependent mechanism of action for the anti-inflammatory activity of a subset of commonly used NSAIDs.

INTRODUCTION

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the oldest and most commonly used medications worldwide. The oldest NSAID, Aspirin, is derived from the active agent responsible for the analgesic and antipyretic properties of the willow bark, which has been used as far back as 1900 BC to treat various maladies (Desborough and Keeling, 2017; MacLagan, 1876; Schmidt, 1934; Stone, 1763). Shortly after aspirin's discovery and commercialization, indomethacin was discovered as a potent NSAID using the first rodent animal model of local inflammation (carrageenan-induced paw inflammation) (Shen, 1963; Winter et al., 1962). The subsequent discovery of the ability of NSAIDs to inhibit cyclooxygenase (COX) to prevent inflammatory prostaglandin formation from arachidonic acid then led to the identification of the isozymes COX1 and COX2 and the proliferation of NSAIDs and COX-specific NSAIDs for the treatment of a wide spectrum of inflammatory diseases (Fu et al., 1990; Vane, 1971).

Given the widespread use of NSAIDs across multiple disease states over the last hundred years, many clinical phenomena

have arisen that have been difficult to reconcile within the paradigm of COX inhibition. Multiple studies have demonstrated that equipotent dosing of NSAIDs with the same COX specificity produce variable outcomes, a phenomenon that had previously been primarily attributed to a combination of pharmacogenetic, pharmacokinetic, and pharmacodynamic differences (Bannuru et al., 2015; Li et al., 2020; Rollason et al., 2014). For example, in a large meta-analyses of arthritis treatment, diclofenac is the most effective NSAID among several other agents with nearly identical COX2 selectivity (da Costa et al., 2017), although among postoperative management, the efficacy of similar NSAIDs are quite variable (Ong et al., 2007). Moreover, NSAID use is associated with both beneficial and detrimental outcomes across multiple diseases, and it has been difficult to ascribe these effects to COX inhibition alone. For example, NSAIDs both prevent and cause heart disease in different contexts (Coxib and traditional NSAID Trialists' (CNT) Collaboration et al., 2013; McGettigan and Henry, 2011). In meta-analyses, ibuprofen and diclofenac increase the risk of myocardial infarction, whereas naproxen—which has similar COX inhibition

profiles—does not (Kearney et al., 2006; Trelle et al., 2011). These paradoxes are also observed in cancer, and there has been a great interest in understanding the COX-independent antitumor mechanisms of NSAIDs (Chubak et al., 2016; Gurpinar et al., 2014). NSAIDs are also implicated in exacerbating allergic disease (Blanca-Lopez et al., 2019; Doña et al., 2012), and NSAIDs with similar COX profiles have markedly different effects on asthma exacerbation (Lo et al., 2016). Indeed, even NSAID-induced gastrointestinal tract damage, one of the most well-known side effects of NSAIDs, cannot be explained solely by the inhibition of COX enzymes (Langenbach et al., 1995). Thus, despite the wealth of data on the potential benefits and harms of NSAIDs, the exact mechanisms underlying these observations is not fully known.

Multiple studies in multiple species have identified noncanonical mechanisms of action of NSAIDs (Gurpinar et al., 2013). The most compelling evidence for this comes from studies utilizing *Caenorhabditis elegans*, which do not express COX isoforms, where NSAIDs extend longevity (Ching et al., 2011; He et al., 2014). Mechanistically, several COX-independent effects of NSAIDs have been proposed, including suppression of NF-κB (Kopp and Ghosh, 1994) and the inflammasome (Smith et al., 2017), as well as a myriad of other potential off-target pathways (Gao et al., 2018). Given the ubiquitous use of NSAIDs and the paradoxical but large effect sizes of NSAIDs across multiple diseases, understanding mechanisms of action of NSAIDs is of great biomedical interest.

In a previous report, we showed that growth/differentiation factor 15 (GDF15) is required for surviving acute systemic inflammation through hepatic metabolic reprogramming (Luan et al., 2019). Historically, *Gdf15* was identified as an NSAID-inducible gene in studies using colorectal cancer cell lines—many of which do not express COX enzymes (Hanif et al., 1996)—in an attempt to understand the correlation between NSAID use and the decreased incidence of colorectal cancer (Chubak et al., 2016). Fittingly, it was originally named NSAID-activated gene 1 (*Nag-1*) (Baek et al., 2001). Based on this, we sought to determine if NSAIDs may have different therapeutic efficacies because they differentially induce GDF15. Here, we report a noncanonical, COX-independent, mechanism of action of NSAIDs that is dependent on the activation of NRF2 in myeloid cells. This has broad implications for the therapeutic use of NSAIDs in a wide range of conditions.

RESULTS

Indomethacin induces GDF15 independent of cyclooxygenases

Given the ability of NSAIDs to induce GDF15 in colorectal cancer cell lines, we sought to determine whether GDF15 could be induced by NSAIDs in primary mouse cells. We challenged bone marrow-derived macrophages (BMDM) with the classical NSAID, indomethacin, and observed robust transcriptional induction (Figure 1A). Indomethacin is a nonselective COX inhibitor with preference for COX1 (Warner et al., 1999). To test whether the ability to induce GDF15 was a function of COX selectivity, we challenged BMDM with a wide spectrum of NSAIDs spanning COX specificities and across multiple doses and observed that only a subset of NSAIDs induced GDF15 transcription and pro-

tein in a dose-dependent fashion (Figures 1B and 1C). We verified that the GDF15-inducing doses of indomethacin and ibuprofen did not cause cell death or induce reactive oxygen species (ROS) (Figures S1A and S1B). For NSAIDs that did not robustly induce GDF15 in this screen, we could only achieve minimal *Gdf15* induction at supratherapeutic doses. Therapeutic doses of ketoprofen, which has a similar COX-specificity profile as indomethacin (Herndon et al., 2008), were unable to induce *Gdf15* at any time point (Figure S1C), and only supratherapeutic, millimolar doses were able to induce GDF15 (Figure S1D). Similar induction of *GDF15* by indomethacin, but not by ketoprofen, was seen in human peripheral blood monocyte-derived macrophages (MDM) (Figure 1D).

Since the ability to induce GDF15 did not depend on COX specificity, we hypothesized that GDF15 induction may be COX independent. To test this, we generated animals where *Ptgs1* and *Ptgs2* (the genes encoding COX1 and 2, respectively) were deleted in Lysozyme 2 (*Lyz2*)-expressing cells, which include many cells of the myeloid lineage (Abram et al., 2014; Shi et al., 2018), and verified that *Ptgs1* and *Ptgs2* expressions were efficiently, but not completely, decreased (Figures S1E and S1F). We were unable to detect *COX2* in resting BMDM by qPCR or western blot, consistent with previous observations that *Ptgs2* is expressed at low levels until induced by various inflammatory stimuli (Angel et al., 1994; Arias-Negrete et al., 1995; Inoue et al., 1995). We found that indomethacin itself induced *Ptgs2* and that this induction was efficiently, but not completely, diminished (Figure S1F). Since others have previously demonstrated that residual COX activity and prostaglandin synthesis retain significant functional signaling properties, which can be both pro- and anti-inflammatory, to estimate the functional deletion of prostaglandin signaling, we characterized known prostaglandin-responsive genes after stimulating BMDMs with lipopolysaccharide (LPS) and found that our transgenic system impacted the expression of these targets (Figure S1G), consistent with our western blot and qPCR approaches to validating deletion efficiency (Cilenti et al., 2021; Funk, 2001; Zelenay et al., 2015). Despite the significant loss of COX1 and COX2, there was no impact on the ability of indomethacin to induce *Gdf15* transcription or on GDF15 secretion into culture supernatant (Figures 1E and 1F). These data demonstrated that NSAIDs could be divided into those that could induce *Gdf15* and those that could not and that the induction of *Gdf15* was largely independent of COX isozymes, although we cannot definitively exclude their contribution, given the incomplete deletion related to limitations of our Cre-loxp approach.

A subset of NSAIDs activates NRF2 and downstream GDF15

Thus, to identify the mechanism of indomethacin-induced *Gdf15* upregulation, we generated BMDMs from animals lacking transcription factors and signaling molecules (Patel et al., 2019; Ratnam et al., 2017; Suzuki et al., 2017) previously implicated in GDF15 regulation (Figure 2A). *Gdf15* induction did not require the essential signaling adaptors for almost all toll-like receptors (TLR), MyD88. We included NRF2-deficient BMDMs because most NSAIDs are carboxylic acid-containing electrophiles, and a study also implicated NRF2 and GDF15 in the mechanism of action of colchicine in hepatocytes (Weng et al., 2021; Zhou

Figure 1. Indomethacin induces GDF15 independent of cyclooxygenases

(A and B) (A) *Gdf15* mRNA expression in BMDMs following stimulation with 0.5 mM indomethacin (n = 3 per group) and (B) at 6 h following stimulation with increasing doses of Aspirin (0.25, 0.5, and 1 mM), indomethacin (0.125, 0.25, and 0.5 mM), ibuprofen (0.125, 0.25, and 0.5 mM), ketoprofen (0.25, 0.5, and 1 mM), naproxen (0.25, 0.5, and 1 mM), etodolac (0.25, 0.5, and 1 mM), and rofecoxib (0.25, 0.5, and 1 mM), in order of increasing specificity of COX2 compared with COX1 (n = 4 per group).

(C) Supernatant GDF15 protein levels following 24 h stimulation with vehicle, 0.5 mM indomethacin, and 0.5 mM ketoprofen (n = 5–8 per group).

(D) *GDF15* mRNA expression in human MDM following stimulation by 0.5 mM indomethacin and 0.5 mM ketoprofen (n = 3 per group).

(E) *Gdf15* mRNA expression of BMDMs stimulated for 6 h with vehicle or 0.5 mM indomethacin (n = 4 per group).

(F) Supernatant GDF15 protein levels from BMDMs stimulated for 24 h with vehicle or 0.5 mM indomethacin (n = 4 per group). All experiments are representative and repeated at least once. Statistics by ANOVA. Data are represented as mean ± standard deviation. *p <.05, ***p <.001, ****p <.0001, ns p >.05.

et al., 2005). Kelch-like ECH-associated protein 1 (KEAP1), the chaperone protein that sequesters NRF2 in the cytosol detects excess cytosolic electrophiles through its cysteine moieties and subsequently releases NRF2 into the nucleus where it activates transcriptional programs important in drug detoxification and maintenance of redox balance (Cuadrado et al., 2019; Yamamoto et al., 2018).

We found that *Gdf15* induction in response to indomethacin required NRF2 (Figure 2A). Using BMDMs from animals in which NRF2 was deleted only in *Lyz2*-expressing cells (Figure S2A), we found that indomethacin-induced GDF15 largely required NRF2 (Figure 2B). Decreased *Gdf15* mRNA and protein were also detected at steady state in these BMDMs (Figures S2B and S2C), suggesting that although NRF2 contributed significantly, but not solely, to basal *Gdf15* expression, it was required for inducibility by NSAIDs. To test if NRF2 activation was sufficient to induce *Gdf15*, we tested two canonical NRF2 activators, sulforaphane and dimethylfumarate (DMF) (Dinkova-Kostova et al., 2002; Foresti et al., 2013; Linker et al., 2011; Scannevin et al., 2012; Zhang et al., 1992), and found that NRF2 activation was

sufficient to induce *Gdf15* in both mouse BMDMs (Figure 2C) and in human MDMs (Figure S2D). However, the ability of DMF to induce GDF15 depended largely, but not completely, on NRF2 (Figures 2D and S2E), consistent with other known mechanisms of action of DMF and consistent with other reported modalities of GDF15 induction. Finally, since NRF2 is responsive to both excess cytosolic electrophiles and also ROS, we tested if ROS could induce *Gdf15* and observed that sodium arsenite, 2,3-dimethoxy-1,4-naphthalenedione (DMNQ), and phenazine methosulfate (PMS) could induce G*df15* in a dose-dependent manner and that this was significantly but incompletely dependent on NRF2 (Figures S2F and S2G). We thus identify NRF2 as a critical transcription factor for the induction of *Gdf15* generally and by a subset of NSAIDs specifically in murine BMDMs.

Since NRF2 was required for GDF15 induction, we asked whether GDF15-inducing NSAIDs, like indomethacin and ibuprofen, also activated canonical NRF2 signaling (Itoh et al., 1997; Itoh et al., 2004; Venugopal and Jaiswal, 1996). Indeed, indomethacin and ibuprofen, but not ketoprofen, induced the expression of canonical NRF2 target genes, *Cat*, *Gar*, *Gclm*,

Figure 2. A subset of NSAIDs activate NRF2 and downstream GDF15

(A) *Gdf15* mRNA expression from BMDMs derived from B6, Myd88$^{-/-}$, Chop$^{-/-}$, Nrf2$^{-/-}$, and Eif2a$^{-/-}$ mice treated for 6 h with vehicle or 0.5 mM indomethacin (n = 4 per group).

(B) Supernatant GDF15 protein levels from BMDMs treated for 24 h with vehicle, 0.5 mM indomethacin, or 0.5 mM ketoprofen (n = 4 per group).

(C) *Gdf15* mRNA expression from BMDMs treated for 6 h with vehicle, sulforaphane, or dimethylfumarate (DMF) (n = 5–6 per group).

(D) Supernatant GDF15 protein levels from BMDMs treated for 24 h with vehicle or DMF (n = 4 per group).

(E and F) Messenger RNA expression of *Cat*, *Gar*, *Gclm*, *Hmox1*, *Nqo1*, *Taldo1* from BMDMs derived from (E) B6 and *Nrf2*$^{-/-}$ mice (n = 4 per group) or (F) *Ptgs1/2* f/f mice following stimulation with vehicle or 0.5 mM indomethacin for 6 h (n = 4 per group).

(G) Immunofluorescence staining of BMDMs for NRF2 (green) and DAPI (blue) following treatment with vehicle or indomethacin.

(legend continued on next page)

Hmox1, *Nqo1*, and *Taldo1* in BMDMs in an NRF2-dependent fashion; the kinetics of other NRF2 target genes activated after indomethacin treatment also mirrored that of *Gdf15* (Figures 2E and S2H–S2J). As with *Gdf15*, ketoprofen was unable to induce *Hmox1* at any dose (Figure S2K), suggesting that it does not activate NRF2 signaling in contrast to indomethacin and ibuprofen. Consistent with the observation that a significant deletion of COX expression did not impact *Gdf15* induction, the induction of NRF2 target genes by indomethacin and ibuprofen also was not impacted by significant loss of COX1 and COX2 (Figures 2F and S2L).

Since NRF2 target genes can be induced by other transcription factors such as hypoxia-inducible factor 1a (Toth and Warfel, 2017), we used immunofluorescence and chromatin immunoprecipitation approaches to confirm that indomethacin caused NRF2 nuclear localization and binding to antioxidant response elements (ARE) in the regulatory regions of *Gdf15* and the canonical NRF2 target *Nqo1*. As predicted, indomethacin treatment of BMDMs indeed caused translocation of NRF2 into the nucleus (Figure 2G). To test if NRF2 bound to regulatory elements in *Gdf15*, we identified a canonical ARE consensus sequence that overlapped with enhancer signatures after scanning for ARE consensus sequences 10 kb upstream and downstream of the transcriptional start site (Figure S3). We found that 4 hours after indomethacin stimulation, NRF2 bound to an enhancer containing two ARE consensus sequences of *Gdf15*; moreover, indomethacin stimulation also resulted in activating histone modifications (H3K27Ac) at this identified control region, indicating that this enhancer is involved in GDF15 transcriptional activation in response to indomethacin (Figure 2H, left). Since we found that indomethacin activated the NRF2 transcriptional program, we tested if indomethacin would also cause NRF2 binding to the ARE consensus sequence in the promoter of *Nqo1* and found that stimulation with indomethacin indeed led to NRF2 binding as well as activating histone modifications (H3K27Ac) at this position (Figure 2H, right). These data collectively demonstrated that a subset of NSAIDs are NRF2 activators and established *Nag-1* (*Gdf15*) as an NRF2-target gene.

Indomethacin activates NRF2 target genes, including *Gdf15*, in *Lyz2*-expressing cells in an NRF2-dependent fashion *in vivo*

Having established some NSAIDs as NRF2 activators and *Gdf15* as an NRF2 target gene in primary mouse and human monocytes/macrophages, we then asked if our *in vitro* observations could be seen *in vivo*. As in BMDMs, we observed that Nrf2$^{-/-}$ mice have less plasma GDF15 levels compared with B6 mice; furthermore, lack of Nrf2 in only *Lyz2*-expressing cells also had decreased the total serum GDF15 levels (Figure 3A). As we had observed in BMDMs, indomethacin, but not ketoprofen, robustly induced plasma GDF15, with a peak concentration at 6 hours after intraperitoneal injection (Figure 3B). Likewise, a sin-

gle injection of the NRF2 activator sulforaphane also induced GDF15 *in vivo* in an NRF2-dependent fashion (Figure S4A). Moreover, bardoxolone, an NRF2 activator in late-stage clinical trials for use in chronic kidney disease, also induced GDF15 *in vivo* both when given in a single bolus or when administered chronically (Figures S4B and S4C).

Consistent with our *in vitro* findings, we found that indomethacin-induced GDF15 was dependent on NRF2 (Figure 3C). Given that *Lyz2*-expressing cells appeared to be important for basal GDF15 levels, we sought to determine whether lack of NRF2 expression in only *Lyz2*-expressing cells altered indomethacin-induced GDF15 levels. Indeed, *Lyz2*-expressing cells produced the majority of plasma GDF15 induced by indomethacin in an NRF2-dependent fashion (Figure 3D). Furthermore, decreased levels COX1 and 2 enzymes in *Lyz2*-expressing cells did not have a significant effect on indomethacin-induced GDF15 levels (Figure 3E). Since inducible GDF15 was completely attenuated in whole body NRF2 deficient mice and roughly 70% of NSAID-induced GDF15 levels depend on *Lyz2*-expressing myeloid cells, other NRF2-expressing cells contribute to NSAID-induced GDF15 *in vivo*. Likewise, the majority of circulating GDF15 induced by sulforaphane, a canonical NRF2 activator, also depended on NRF2 expression specifically in *Lyz2*-expressing cells (Figure 3F), suggesting a more general role for this cell lineage in GDF15 regulation and production downstream of NRF2 activation. As we consistently observed transient induction of GDF15 following a single dose of indomethacin, we sought to determine whether this was also true for other NRF2 target genes *in vivo*. *Hmox1* expression in the liver peaked at 6 hours and then decreased, similarly to serum GDF15 (Figure 3G).

Having established that indomethacin and the canonical NRF2 activator sulforaphane can induce GDF15 *in vivo*, we explored whether elevated plasma GDF15 levels were indicative of activation of NRF2 programs in response to indomethacin. To test for NRF2 activation *in vivo*, we first screened organs from B6 mice for transcriptional induction after sulforaphane injection to identify potential organs most responsive to systemic NRF2 activation and identified robust induction of *Gdf15* and *Nqo1* primarily in the liver and kidney (Figures S4D and S4E). We next sought to determine whether this effect was dependent on NRF2. Consistent with the requirement of NRF2 for NSAID-induced GDF15, both indomethacin and sulforaphane induced NRF2 target genes *Gdf15*, *Hmox1*, and *Nqo1* in the liver and kidney in a manner dependent on NRF2 in *Lyz2*-expressing cells (Figures 3H and S4F). Indomethacin-induced upregulation of *Gdf15*, *Hmox1*, and *Nqo1* in liver and kidney was independent of COX1 and 2 expressions in *Lyz2*-expressing cells (Figures 3I and S4G). Collectively, these data demonstrated that although steady-state GDF15 levels partially require NRF2, NSAID-induced GDF15 required NRF2 primarily in cells of the myeloid lineage and NSAIDs induced NRF2 target genes primarily in myeloid cells expressing *Lyz2* in the liver and kidney *in vivo*.

(H) Chromatin immunoprecipitation of *Gdf15* and *Nqo1*. ChIP was performed on BMDM stimulated for 4 h with vehicle or indomethacin using anti-NRF2 (top, red), anti-H3K27Ac (bottom, black), or control (IgG) antibody, and qPCR was performed with primers spanning 1 kb upstream and downstream of the identified ARE consensus sequence (Figure S3) in the regulatory elements of *Gdf15* (left) and *Nqo1* (right). Representative of 2 independent experiments. All experiments are representative and repeated at least once. Statistics by ANOVA. Data are represented as mean ± standard deviation. *p <.05, **p < 0.01, ***p <.001, ****p <.0001, ns p >.05.

Figure 3. Indomethacin activates NRF2 target genes, including GDF15, in NRF2-depdendent and COX1/2-independent manner in *Lyz2*-expressing cells *in vivo*

(A) Baseline GDF15 serum levels (n = 3–10 per group).

(B) Serum GDF15 protein levels in B6 mice following intraperitoneal injection with vehicle, 15 mg/kg indomethacin or 15 mg/kg ketoprofen (n = 3–5 per group).

(C–E) Serum GDF15 protein levels in (C) $Nrf2^{-/-}$, (D) $Nrf2$ f/f, and (E) $Ptgs1/2$ f/f mice following intraperitoneal injection of 15 mg/kg indomethacin (n = 3–6 per group).

(F) Serum GDF15 protein levels following injection of 25 mg/kg sulforaphane (n = 3–7 per group).

(G) $Hmox1$ RNA expression of bulk liver in animal treated with vehicle or indomethacin at the indicated time points (n = 3–4 per group).

(H and I) Kidney $Gdf15$, $Hmox1$, and $Nqo1$ mRNA expression 6 h following intraperitoneal injection of 15 mg/kg indomethacin or 50 mg/kg sulforaphane in (H) Nrf f/f mice (n = 3–6 per group) or (I) $Ptgs1/2$ f/f mice (n = 5–6 per group). All experiments are representative and repeated at least once. Statistics by ANOVA. Data are represented as mean ± standard deviation. *p <.05, **p < 0.01, ***p <.001, ****p <.0001, ns p > 0.05.

The Cysteine 151 (C151) of KEAP1 is necessary for activation of NRF2 target genes by indomethacin

Electrophilic xenobiotic activation of NRF2 requires binding to cysteine moieties in the chaperone protein KEAP1. Of these cysteine residues, C151 has previously been shown to be essential for activation of NRF2 by DMF, sulforaphane, and bardoxolone (Dayalan Naidu et al., 2018; Takaya et al., 2012), all of which we discovered activated GDF15 *in vivo* and *in vitro*. Thus,

to test the requirement of C151 in indomethacin-induced NRF2 pathway activation, we obtained an animal where a single point mutation was made at that position from cysteine to serine (C151S) (Saito et al., 2016). Using this transgenic animal, we made BMDMs and found that the ability of indomethacin to induce $Gdf15$ required C151 (Figure 4A). Likewise, the NRF2-mediated transcriptional program also required C151 (Figure 4B), consistent with results obtained using NRF2-deficient

Figure 4. Cysteine 151 of KEAP1 is required for NRF2 activation by indomethacin
(A) *Gdf15* mRNA levels in BMDM generated from C151S KEAP1 transgenic animals and littermate controls 6 h after stimulation with indomethacin or ketoprofen (n = 4 per group).
(B) NRF2 target gene expression in BMDM generated from C151S KEAP1 transgenic animals and littermate controls 6 h after stimulation with indomethacin (n = 4 per group).
(C) Baseline GDF15 serum levels in C151S KEAP1 mice and controls (n = 5–7 per group).
(D) Plasma GDF15 levels after an intraperitoneal injection of 15 mg/kg indomethacin at the indicated time points in C151S and wild-type animals (n = 5–7 per group).
(E) mRNA expression of *Gdf15*, *Hmox1*, and *Nqo1* at 6 h from bulk liver of C151S and wild-type animals after treatment with 15 mg/kg indomethacin (n = 4 per group). All experiments are representative and repeated at least once. Statistics by ANOVA. Data are represented as mean ± standard deviation. **p < 0.01, ***p <.001, ****p <.0001.

cells (Figures 2 and 3). To test the requirement of C151 *in vivo*, we challenged C151S mice with indomethacin. We found that basal GDF15 was also partially dependent on C151 (Figure 4C), suggesting that an endogenous factor may be required to maintain steady-state levels of basal GDF15. Consistent with our observation that indomethacin-induced GDF15 was completely dependent on NRF2, we also found that the induction of serum GDF15 by indomethacin was completely dependent on the C151 residue in KEAP1 (Figure 4D). Finally, we sacrificed C151S animals after indomethacin challenge and assessed the ability of indomethacin to induce NRF2 target genes in the liver and observed complete abrogation of expression in the setting of C151 disruption (Figure 4E). Altogether, we demonstrated that a subset of NSAIDs activate GDF15 through NRF2 in a mechanism that is dependent on the C151 residue in KEAP1.

Indomethacin reduces inflammation in endotoxemia and gout via an NRF2-dependent, KEAP1 C151S-dependent, GDF15-independent mechanism
We next wanted to test the contribution of the NRF2-activating properties of NSAID to its anti-inflammatory effects. NRF2 activation reduces the inflammatory output of myeloid cells via a variety of mechanisms (Kobayashi et al., 2016; Mills et al., 2018). We thus hypothesized that NRF2-activating NSAIDs would be more effective in reducing inflammation *in vivo* than non-NRF2-activating NSAIDs and that indomethacin may be less effective in reducing inflammation in the absence of NRF2 in *Lyz2*-expressing cells.

First, we tested if the same weight-based dose of ketoprofen would be as effective as indomethacin in reducing inflammation using the endotoxemia model of sterile systemic inflammation. We found that indomethacin was more effective than ketoprofen when using loss of core body temperature (CBT), a readout of

Figure 5. Indomethacin reduces inflammation in endotoxemia and gout via an NRF2-dependent, GDF15-independent, and COX1/2-independent mechanisms

(A) Temperature curve for B6 mice following intraperitoneal injection with LPS and vehicle, indomethacin, or ketoprofen (area under the curve [AUC] p < 0.0001, n = 4 per group).

(B–D) Temperature curve for (B) *Nrf2* f/f mice (AUC p < 0.0085, n = 5 per group), (C) C151S mice (AUC < 0.001, n = 5 per group), and (D) in B6 or *Nrf2*$^{-/-}$ mice treated with vehicle or indomethacin with or without recombinant GDF15 or protein control (BSA) (AUC p < 0.01, n = 4–5 per group). (E) Serum IL-1β levels in B6 and *Nrf2*$^{-/-}$ mice 24 h following intraperitoneal injection of LPS and vehicle or indomethacin (n = 4–5 per group).

(F) Log$_2$ fold change in mRNA expression of inflammatory markers in the liver of B6 and *Nrf2*$^{-/-}$ mice injected intraperitoneally with LPS and vehicle or indomethacin (n = 3–5 per group).

(legend continued on next page)

inflammation and disease severity (Figure 5A). The therapeutic efficacy of indomethacin was not lost upon the significant reduction of *Ptgs1* and Ptgs*2* expressions in *Lyz2*-expressing cells (Figure S5A) but rather was attenuated when *Nrf2* was deleted in *Lyz2*-expressing cells (Figure 5B), which phenocopied constitutive *Nrf2* deletion (Figure S5B). Likewise, C151 of KEAP1 was also required for the protective effects of indomethacin (Figure 4C). Having shown that indomethacin activates NRF2 and that *Gdf15* is an NRF2 target gene, we next sought to determine whether GDF15 was mediating the protective effects of indomethacin in the endotoxemia model. As such, we treated WT and $Nrf2^{-/-}$ mice with recombinant GDF15 in the endotoxemia model. Recombinant GDF15 did not recapitulate the effects of indomethacin on temperature in the endotoxemia model in WT or $Nrf2^{-/-}$ mice (Figure 5D).To test if GDF15 was required for the effects of indomethacin, we acutely inhibited GDF15 with anti-GDF15 antibody (Luan et al., 2019), which did not attenuate the benefits of indomethacin treatment on CBT in the endotoxemia model, a result we confirmed using animals with constitutive genetic deletion of *Gdf15* (Liu et al., 2020) (Figures S4C and S4D). These data suggest that although GDF15 may be mediating other physiological processes not assayed for in these experiments, GDF15 is not necessary or sufficient to mediate the beneficial effects of indomethacin in endotoxemia that depend on NRF2 and C151 of KEAP1.

Consistent with improved thermoregulation and protection against loss of CBT, indomethacin also induced inhibition of proinflammatory cytokines (Figure S4E), including circulating IL-1β, in response to endotoxemia. Reduction of IL-1β in response to indomethacin during endotoxemia was dependent on NRF2 (Figure 5E). Since the liver and kidney were identified as the main sites of NRF2 activation after indomethacin injection, we looked at the effect of indomethacin on inflammatory transcripts in the liver and kidney in LPS challenged wild-type and *Nrf2*-deficient animals. We found that indomethacin decreased a number of inflammatory transcripts in the liver (Figure 5F). This correlated with reduced liver damage as evidenced by reduced plasma aminotransferase levels (Figure 5G). Consistent with our findings of decreased systemic inflammation, the reduction in liver inflammation and injury also occurred in an NRF-dependent fashion. We did not detect differences in the number of cellular infiltrates in the liver (Figure S4F). Similar to our previous findings, indomethacin but not ketoprofen induced NRF2 target genes in the liver of endotoxemic animals (Figure 5H). We did not detect large differences in the kidney, either with regards to damage or inflammation (Figures S5G and S5H) potentially because of the negative COX-dependent effects on renal perfusion, particularly in inflammatory settings (Brater et al., 2001). Conversely, we did detect differences in damage and inflammation in the heart. We found that indomethacin, but not ketoprofen, mediated increased cardiac dysfunction and inflammation in an NRF-2-dependent fashion (Figures S5I and S5J).

These findings are reminiscent of similar observations seen in clinical trials using the NRF2 activator, bardoxolone, where bardoxolone improved kidney function at the expense of cardiovascular toxicity that ultimately led to trial termination (de Zeeuw et al., 2013).

Finally, we utilized a model of local inflammation, acute gout, similar to the carrageenen-induced paw inflammatory model initially used to discover indomethacin (Shen, 1963; Winter et al., 1962). We chose this model because indomethacin remains a first-line agent in the management of acute gout (Schumacher, 2004). In this model, uric acid crystals are injected into the footpad, leading to measurable gross swelling of the foot similar to acute gouty arthritis, which most commonly occurs in the foot of patients with gout (Mallinson et al., 2014). Similar to our findings in the endotoxemia model, mice treated with indomethacin had reduced inflammation in a fashion that was dependent on NRF2 expression and not impacted by significant reduction in *Ptgs1* and *Ptgs2* expressions in *Lyz2*-expressing cells (Figures 5I and 5J). Thus, we demonstrate that NRF2 activation in myeloid cells contributes significantly to the anti-inflammatory properties of certain NSAIDs and that certain NSAIDs may be more potent anti-inflammatory agents than others due to their differential ability to activate NRF2 through KEAP1 C151.

DISCUSSION

NSAIDs are among the most ubiquitous medications used worldwide. Although *COX1* and *2* inhibition is clearly a major component of the anti-inflammatory action of NSAIDs, these data suggest an additional COX-independent mechanism of action of some NSAIDs that accounts for at least some of the anti-inflammatory properties of NSAIDs. The differences in the ability of different NSAIDs to activate NRF2, which we demonstrate is dependent on the Cysteine 151 in KEAP1, may in part bely the differential efficacies of NSAIDs in the treatment of inflammatory diseases as well as the unexpected properties of certain NSAIDs when used in a variety of settings, since NRF2 activation has been implicated in cancer (Rojo de la Vega et al., 2018), allergic disease (Al-Harbi et al., 2019; Nagashima et al., 2019; Ogawa et al., 2020; Rangasamy et al., 2005; Wu et al., 2019), and cardiovascular disease (Chen and Maltagliati, 2018).

The biological role of GDF15 in the context of NSAIDs administered during inflammation remains unclear. In our studies, we did not observe large effects of manipulating GDF15 on the response to endotoxemia, but we also did not perform more granular analyses dissecting this specific aspect, since the central hypothesis we were testing centered around the dependence of an NRF2-activating NSAID on NRF2 activation of which GDF15 induction is one part. GDF15 biology is an area of research across disciplines and, like other endocrine cytokines,

(G) Serum alanine transferase (ALT) activity 20 h following intraperitoneal injection with LPS and vehicle or indomethacin (n = 4–5 per group).

(H) Liver *Nqo1* and *Cat* mRNA expression following intraperitoneal injection of vehicle, indomethacin, or ketoprofen (n = 3–5 per group).

(I and J) Footpads of (I) *Ptgs1/2* f/f mice (n = 3–4 per group) and (J) *Nrf2* f/f mice (n = 4–8 per group) injected intradermally with PBS or monosodium urate (MSU) and then treated with intraperitoneal injections of vehicle or indomethacin. Foot diameter was normalized to baseline foot diameter. All experiments are representative and repeated at least once. Statistics by ANOVA. Data are represented as mean ± standard deviation. *p <.05, **p < 0.01, ***p <.001, ****p <.0001, ns p >.05.

appears to produce different physiologic effects as a function of the host context (Coll et al., 2020; Day et al., 2019; Luan et al., 2019; Santos et al., 2020; Weng et al., 2021), and its "core" biology remains to be elucidated.

Our observation that NSAIDs activate NRF2 begins to reconcile previous observations that NSAID treatment enhanced lifespan in *Caenorhabditis elegans* (Ching et al., 2011; He et al., 2014), whose genomes do not encode cyclooxygenase isoforms but do encode *Nrf2*. NRF2 activation has been implicated in aging, longevity, and reduction of cellular stress associated with detoxification of free radicals (Castiglione et al., 2020; Lewis et al., 2015; Lombard et al., 2020). Indeed, it is possible that one reason that only certain NSAIDs increase longevity in studies that span multiple species, and especially in those that do not encode cyclooxygenase isozymes in their genomes, is because they engage NRF2 pathways, which are simultaneously cytoprotective, through the detoxification of harmful free radicals and also anti-inflammatory. Since cellular stress and inflammation are highly intertwined, it is possible that our observations in improved organ function and inflammation in the models of acute inflammation we used are simultaneously a result of both the anti-inflammatory and the cytoprotective effects of the NRF2-activating NSAIDs.

Our findings potentially explain long-observed seemingly paradoxical properties of NSAIDs that cannot be explained by COX1 and 2 expressions. They may also inform limitations and potential of NRF2 activators in the treatment of inflammatory diseases, which are in clinical trials for diseases ranging from multiple sclerosis, Alzheimer's Disease, chronic kidney disease, diabetes mellitus type 2, asthma, rheumatoid arthritis, psoriasis, and various cancers (Cuadrado et al., 2019; Robledinos-Antón et al., 2019). Likewise, NRF2-activating NSAIDs could be considered for use in diseases that respond to NRF2 activators, such as multiple sclerosis. Thus, our findings, if they bear out in human studies, may significantly impact prescribing and utilization behaviors of NSAIDs.

Like with COX inhibition, there is likely an optimal amount of NRF2 activation where the antioxidant and anti-inflammatory actions of NRF2 are not negatively counterbalanced by the costs related to excessive activation. This has been observed in the context of oncogenesis, where, initially, low levels of NRF2 activation and subsequent antioxidant and anti-inflammatory properties are beneficial in reducing the development of oncogenic mutations and tumor promoting environment, but with the development of a tumor, mutations that lead to unregulated NRF2 activation likely drive cellular survival and proliferation (Sporn and Liby, 2012). Similarly, NSAIDs have anti-inflammatory properties through COX inhibition but at the cost of gastrointestinal damage, decreased renal perfusion, increased risk of bleeding, and cardiovascular disease (Schjerning et al., 2020).

Finally, we show that GDF15 is a soluble marker of NRF2 activation and implicate other inducers of GDF15 as potential NRF2 activators. Metformin also induces GDF15, and the antidiabetic effects of metformin were partially shown to be dependent on GDF15 (Coll et al., 2020; Day et al., 2019). The transcriptional control of this observation remains unclear. Given our identification of NRF2, a xenobiotic sensor, as the key transcription factor in inducing GDF15 in the context of its original discovery as an NSAID-activated gene, it remains to be seen how many other manmade xenobiotics also exert some of their beneficial or harmful actions by engaging NRF2 pathways. Canagliflozin, an antidiabetic and cardioprotective drug that is thought to primarily exert its mechanism of action by inhibition of the Sodium/Glucose Transport Protein 2, activates NRF2 to mediate antioxidant and anti-inflammatory effects (Behnammanesh et al., 2020; Hasan et al., 2020). Furthermore, colchicine activates GDF15 in hepatocytes, and both NRF2 and GDF15 are required for the anti-inflammatory effects of colchicine (Weng et al., 2021). In this study, GDF15 is proposed to be a hepatokine with the action of GDF15 directly on myeloid cells, implicating another receptor for GDF15 that has yet to be characterized. Although different methods for cell-specific deletion of *Nrf2* were employed in this study (siRNA) compared with ours (Cre-loxp), both studies taken together suggest GDF15 is likely produced by both myeloid cells and hepatocytes, and likely other parenchymal cells in the kidney (Mulderrig et al., 2021), with all compartments contributing to the circulating levels. The significance of these respective responding cells in contributing to the absolute level of circulating GDF15, which act distally on neurons in the area postrema (Hsu et al., 2017; Mullican et al., 2017) and possibly on myeloid and other cells in a yet undefined mechanism of action, and whether NRF2 is required in all of these cellular compartments is yet to be understood.

For therapeutics designed to activate NRF2, such as DMF and bardoxolone, and other therapeutics that we and others are now identifying as "off-target" NRF2 activators, it remains to be understood to what extent their therapeutic efficacy are "on-target," NRF2-dependent, and/or GDF15-dependent. Given the pleiotropic role of GDF15, it is possible that GDF15 may play different roles in different contexts (Borner et al., 2020; Gil et al., 2019; Kim et al., 2018; Luan et al., 2019; Mullican et al., 2017; Patel et al., 2019), and much work remains in elucidating the biology of GDF15 and its therapeutic potential in different disease states. Our identification of a subset of NSAIDs as NRF2 activators and GDF15 as an NRF2 target gene may help reconcile the many paradoxical effects of NSAIDs observed across many disease states and have significant clinical and biological implications for other allopathic xenobiotics.

Limitations of the study

An important limitation in the interpretation of our studies is in the inability to completely delete the *Ptgs1* and *Ptgs2* isozymes. Thus, although our observed effects definitively require NRF2 and KEAP1 C151, it remains possible that the minimal remaining COX activity is also required as others have shown that even residual COX activity and prostaglandin synthesis have large biological effects (Zelenay et al., 2015). Secondly, although we attempted to identify NSAID adducts to KEAP1 using various pull-down and mass spectroscopic approaches, we were unable to definitively identify novel adducts, and the assumption that C151 forms an adduct with NSAIDs or their modifications once metabolized by cells is likely but speculative. Thus, the precise chemical basis for our observation that bely why some NSAIDs engage NRF2 and activate GDF15 although others do not remains to be elucidated. Finally, the translatability of this study to humans beyond the *in vitro* experiments performed in this study is yet to be determined.

Immunity
Article

CellPress

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
  - Mice
  - Cell culture
- METHOD DETAILS
  - Cell stimulation
  - RNA extraction and quantification
  - Cytokine and tissue injury marker analysis
  - Immunofluorescence
  - ChIP quantitative PCR
  - Western blot
  - Flow cytometry
  - *In vivo* inflammatory mouse models
- QUANTIFICATION AND STATISTICAL ANALYSIS

AUTHOR CONTRIBUTIONS

Conceptualization, B.K.H., A.E., A.W., H.H.L., and H.T.; methodology, B.K.H., A.E., A.W., H.H.L., H.T., P.T., C.Z., D.A.W., S.D.P., and K.I.-W.; formal analysis, B.K.H., A.E., A.W., and H.H.L.; investigation, B.K.H., A.E., A.W., H.H.L., H.T., P.T., D.A.W., K.I.-W., and S.D.P.; resources, A.W., and H.H.L., and C.Z.; writing – original draft, B.K.H., A.E., H.H.L., and A.W.; writing – review & editing, B.K.H., A.E., H.H.L., D.A.W., H.T., P.T., S.D.P., and K.I.-W.; funding acquisition, A.W.

REFERENCES

Abram, C.L., Roberge, G.L., Hu, Y., and Lowell, C.A. (2014). Comparative analysis of the efficiency and specificity of myeloid-Cre deleting strains using ROSA-EYFP reporter mice. J. Immunol. Methods *408*, 89–100.

Al-Harbi, N.O., Nadeem, A., Ahmad, S.F., AlThagfan, S.S., Alqinyah, M., Alqahtani, F., Ibrahim, K.E., and Al-Harbi, M.M. (2019). Sulforaphane treatment reverses corticosteroid resistance in a mixed granulocytic mouse model of asthma by upregulation of antioxidants and attenuation of Th17 immune responses in the airways. Eur. J. Pharmacol. *855*, 276–284.

Angel, J., Berenbaum, F., Le Denmat, C., Nevalainen, T., Masliah, J., and Fournier, C. (1994). Interleukin-1-induced prostaglandin E2 biosynthesis in human synovial cells involves the activation of cytosolic phospholipase A2 and cyclooxygenase-2. Eur. J. Biochem. *226*, 125–131.

Arias-Negrete, S., Keller, K., and Chadee, K. (1995). Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem. Biophys. Res. Commun. *208*, 582–589.

Baek, S.J., Kim, K.S., Nixon, J.B., Wilson, L.C., and Eling, T.E. (2001). Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities. Mol. Pharmacol. *59*, 901–908.

Bannuru, R.R., Schmid, C.H., Kent, D.M., Vaysbrot, E.E., Wong, J.B., and McAlindon, T.E. (2015). Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann. Intern. Med. *162*, 46–54.

Behnammanesh, G., Durante, G.L., Khanna, Y.P., Peyton, K.J., and Durante, W. (2020). Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: role of heme oxygenase-1. Redox Biol. *32*, 101527.

Blanca-Lopez, N., Soriano, V., Garcia-Martin, E., Canto, G., and Blanca, M. (2019). NSAID-induced reactions: classification, prevalence, impact, and management strategies. J. Asthma Allergy *12*, 217–233.

Borner, T., Shaulson, E.D., Ghidewon, M.Y., Barnett, A.B., Horn, C.C., Doyle, R.P., Grill, H.J., Hayes, M.R., and De Jonghe, B.C. (2020). GDF15 induces anorexia through nausea and emesis. Cell Metab. *31*, 351–362.e5.

Brater, D.C., Harris, C., Redfern, J.S., and Gertz, B.J. (2001). Renal effects of COX-2-selective inhibitors. Am. J. Nephrol. *21*, 1–15.

Castiglione, G.M., Xu, Z., Zhou, L., and Duh, E.J. (2020). Adaptation of the master antioxidant response connects metabolism, lifespan and feather development pathways in birds. Nat. Commun. *11*, 2476.

Chen, Q.M., and Maltagliati, A.J. (2018). Nrf2 at the heart of oxidative stress and cardiac protection. Physiol. Genomics *50*, 77–97.

Ching, T.T., Chiang, W.C., Chen, C.S., and Hsu, A.L. (2011). Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity. Aging Cell *10*, 506–519.

Chubak, J., Whitlock, E.P., Williams, S.B., Kamineni, A., Burda, B.U., Buist, D.S., and Anderson, M.L. (2016). Aspirin for the prevention of cancer incidence and mortality: systematic evidence reviews for the U.S. Preventive Services Task Force. Ann. Intern. Med. *164*, 814–825.

Cilenti, F., Barbiera, G., Caronni, N., Iodice, D., Montaldo, E., Barresi, S., Lusito, E., Cuzzola, V., Vittoria, F.M., Mezzanzanica, L., et al. (2021). A PGE2-MEF2A axis enables context-dependent control of inflammatory gene expression. Immunity *54*, 1665–1682.e14.

Colegio, O.R., Chu, N.Q., Szabo, A.L., Chu, T., Rhebergen, A.M., Jairam, V., Cyrus, N., Brokowski, C.E., Eisenbarth, S.C., Phillips, G.M., et al. (2014). Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature *513*, 559–563.

Coll, A.P., Chen, M., Taskar, P., Rimmington, D., Patel, S., Tadross, J.A., Cimino, I., Yang, M., Welsh, P., Virtue, S., et al. (2020). GDF15 mediates the effects of metformin on body weight and energy balance. Nature *578*, 444–448.

Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala, N., Emberson, J., Merhi, A., Abramson, S., Arber, N., Baron, J.A., Bombardier, C., Cannon, C., Farkouh, M.E., et al. (2013). Vascular and upper

gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet *382*, 769–779.

Crestani, F., Seguy, F., and Dantzer, R. (1991). Behavioural effects of peripherally injected interleukin-1: role of prostaglandins. Brain Res. *542*, 330–335.

Cuadrado, A., Rojo, A.I., Wells, G., Hayes, J.D., Cousin, S.P., Rumsey, W.L., Attucks, O.C., Franklin, S., Levonen, A.L., Kensler, T.W., and Dinkova-Kostova, A.T. (2019). Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat. Rev. Drug Discov. *18*, 295–317.

da Costa, B.R., Reichenbach, S., Keller, N., Nartey, L., Wandel, S., Jüni, P., and Trelle, S. (2017). Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet *390*, e21–e33.

Day, E.A., Ford, R.J., Smith, B.K., Mohammadi-Shemirani, P., Morrow, M.R., Gutgesell, R.M., Lu, R., Raphenya, A.R., Kabiri, M., McArthur, A.G., et al. (2019). Metformin-induced increases in GDF15 are important for suppressing appetite and promoting weight loss. Nat. Metab. *1*, 1202–1208.

Dayalan Naidu, S., Muramatsu, A., Saito, R., Asami, S., Honda, T., Hosoya, T., Itoh, K., Yamamoto, M., Suzuki, T., and Dinkova-Kostova, A.T. (2018). C151 in KEAP1 is the main cysteine sensor for the cyanoenone class of NRF2 activators, irrespective of molecular size or shape. Sci. Rep. *8*, 8037.

de Zeeuw, D., Akizawa, T., Audhya, P., Bakris, G.L., Chin, M., Christ-Schmidt, H., Goldsberry, A., Houser, M., Krauth, M., Lambers Heerspink, H.J., et al. (2013). Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. *369*, 2492–2503.

Desborough, M.J.R., and Keeling, D.M. (2017). The aspirin story - from willow to wonder drug. Br. J. Haematol. *177*, 674–683.

Dinkova-Kostova, A.T., Holtzclaw, W.D., Cole, R.N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., and Talalay, P. (2002). Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc. Natl. Acad. Sci. USA *99*, 11908–11913.

Doña, I., Blanca-López, N., Torres, M.J., García-Campos, J., García-Núñez, I., Gómez, F., Salas, M., Rondón, C., Canto, M.G., and Blanca, M. (2012). Drug hypersensitivity reactions: response patterns, drug involved, and temporal variations in a large series of patients. J. Investig. Allergol. Clin. Immunol. *22*, 363–371.

Foresti, R., Bains, S.K., Pitchumony, T.S., de Castro Brás, L.E., Drago, F., Dubois-Randé, J.L., Bucolo, C., and Motterlini, R. (2013). Small molecule activators of the Nrf2-HO-1 antioxidant axis modulate heme metabolism and inflammation in BV2 microglia cells. Pharmacol. Res. *76*, 132–148.

Fornes, O., Castro-Mondragon, J.A., Khan, A., van der Lee, R., Zhang, X., Richmond, P.A., Modi, B.P., Correard, S., Gheorghe, M., Baranašić, D., et al. (2020). JASPAR 2020: update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. *48*, D87–D92.

Fu, J.Y., Masferrer, J.L., Seibert, K., Raz, A., and Needleman, P. (1990). The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. *265*, 16737–16740.

Funk, C.D. (2001). Prostaglandins and leukotrienes: advances in eicosanoid biology. Science *294*, 1871–1875.

Gao, J., Mfuh, A., Amako, Y., and Woo, C.M. (2018). Small molecule interactome mapping by photoaffinity labeling reveals Binding Site hotspots for the NSAIDs. J. Am. Chem. Soc. *140*, 4259–4268.

Gil, C.I., Ost, M., Kasch, J., Schumann, S., Heider, S., and Klaus, S. (2019). Role of GDF15 in active lifestyle induced metabolic adaptations and acute exercise response in mice. Sci. Rep. *9*, 20120.

Gurpinar, E., Grizzle, W.E., and Piazza, G.A. (2013). COX-independent mechanisms of cancer chemoprevention by anti-inflammatory drugs. Front. Oncol. *3*, 181.

Gurpinar, E., Grizzle, W.E., and Piazza, G.A. (2014). NSAIDs inhibit tumorigenesis, but how? Clin. Cancer Res. *20*, 1104–1113.

Hanif, R., Pittas, A., Feng, Y., Koutsos, M.I., Qiao, L., Staiano-Coico, L., Shiff, S.I., and Rigas, B. (1996). Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem. Pharmacol. *52*, 237–245.

Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Chowdhury, F.I., Nayan, S.I., Rahman, M.M., Khan, F., Subhan, N., and Alam, M.A. (2020). Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci. Rep. *10*, 14459.

He, C., Tsuchiyama, S.K., Nguyen, Q.T., Plyusnina, E.N., Terrill, S.R., Sahibzada, S., Patel, B., Faulkner, A.R., Shaposhnikov, M.V., Tian, R., et al. (2014). Enhanced longevity by ibuprofen, conserved in multiple species, occurs in yeast through inhibition of tryptophan import. PLoS Genet. *10*, e1004860.

Herndon, C.M., Hutchison, R.W., Berdine, H.J., Stacy, Z.A., Chen, J.T., Farnsworth, D.D., Dang, D., and Fermo, J.D.; Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy (2008). Management of chronic nonmalignant pain with nonsteroidal antiinflammatory drugs. Joint opinion statement of the Ambulatory Care, Cardiology, and Pain and Palliative Care Practice and Research Networks of the American College of Clinical Pharmacy. Pharmacotherapy *28*, 788–805.

Hsu, J.Y., Crawley, S., Chen, M., Ayupova, D.A., Lindhout, D.A., Higbee, J., Kutach, A., Joo, W., Gao, Z., Fu, D., et al. (2017). Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature *550*, 255–259.

Inoue, H., Yokoyama, C., Hara, S., Tone, Y., and Tanabe, T. (1995). Transcriptional regulation of human prostaglandin-endoperoxide synthase-2 gene by lipopolysaccharide and phorbol ester in vascular endothelial cells. Involvement of both nuclear factor for interleukin-6 expression site and cAMP response element. J. Biol. Chem. *270*, 24965–24971.

Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997). An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. *236*, 313–322.

Itoh, K., Tong, K.I., and Yamamoto, M. (2004). Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic. Biol. Med. *36*, 1208–1213.

Kavian, N., Mehlal, S., Jeljeli, M., Saidu, N.E.B., Nicco, C., Cerles, O., Chouzenoux, S., Cauvet, A., Camus, C., Ait-Djoudi, M., et al. (2018). The Nrf2-antioxidant response element signaling pathway controls fibrosis and autoimmunity in scleroderma. Front. Immunol. *9*, 1896.

Kearney, P.M., Baigent, C., Godwin, J., Halls, H., Emberson, J.R., and Patrono, C. (2006). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ *332*, 1302–1308.

Kim, K.H., Kim, S.H., Han, D.H., Jo, Y.S., Lee, Y.H., and Lee, M.S. (2018). Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice. Sci. Rep. *8*, 6789.

Kobayashi, E.H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., and Yamamoto, M. (2016). Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. *7*, 11624.

Kopp, E., and Ghosh, S. (1994). Inhibition of NF-kappa B by sodium salicylate and aspirin. Science *265*, 956–959.

Langenbach, R., Morham, S.G., Tiano, H.F., Loftin, C.D., Ghanayem, B.I., Chulada, P.C., Mahler, J.F., Lee, C.A., Goulding, E.H., Kluckman, K.D., et al. (1995). Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration. Cell *83*, 483–492.

Lewis, K.N., Wason, E., Edrey, Y.H., Kristan, D.M., Nevo, E., and Buffenstein, R. (2015). Regulation of Nrf2 signaling and longevity in naturally long-lived rodents. Proc. Natl. Acad. Sci. USA *112*, 3722–3727.

Li, M., Yu, C., and Zeng, X. (2020). Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis. BMJ Open *10*, e036748.

Immunity
Article

CellPress

Liang, X., Bittinger, K., Li, X., Abernethy, D.R., Bushman, F.D., and FitzGerald, G.A. (2015). Bidirectional interactions between indomethacin and the murine intestinal microbiota. eLife *4*, e08973.

Linker, R.A., Lee, D.H., Ryan, S., van Dam, A.M., Conrad, R., Bista, P., Zeng, W., Hronowsky, X., Buko, A., Chollate, S., et al. (2011). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain *134*, 678–692.

Liu, J., Kumar, S., Heinzel, A., Gao, M., Guo, J., Alvarado, G.F., Reindl-Schwaighofer, R., Krautzberger, A.M., Cippà, P.E., McMahon, J., et al. (2020). Renoprotective and immunomodulatory effects of GDF15 following AKI invoked by ischemia-reperfusion injury. J. Am. Soc. Nephrol. *31*, 701–715.

Lo, P.C., Tsai, Y.T., Lin, S.K., and Lai, J.N. (2016). Risk of asthma exacerbation associated with nonsteroidal anti-inflammatory drugs in childhood asthma: A nationwide population-based cohort study in Taiwan. Med. (Baltim.) *95*, e5109.

Lombard, D.B., Kohler, W.J., Guo, A.H., Gendron, C., Han, M., Ding, W., Lyu, Y., Ching, T.T., Wang, F.Y., Chakraborty, T.S., et al. (2020). High-throughput small molecule screening reveals Nrf2-dependent and -independent pathways of cellular stress resistance. Sci. Adv. *6*, eaaz7628.

Luan, H.H., Wang, A., Hilliard, B.K., Carvalho, F., Rosen, C.E., Ahasic, A.M., Herzog, E.L., Kang, I., Pisani, M.A., Yu, S., et al. (2019). GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell *178*, 1231–1244.e11.

MacLagan, T. (1876). The treatment of acute rheumatism by salicin. Lancet *I*, 585.

Mallinson, P.I., Reagan, A.C., Coupal, T., Munk, P.L., Ouellette, H., and Nicolaou, S. (2014). The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases. Skeletal Radiol. *43*, 277–281.

McGettigan, P., and Henry, D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLOS Med. *8*, e1001098.

Mills, E.L., Ryan, D.G., Prag, H.A., Dikovskaya, D., Menon, D., Zaslona, Z., Jedrychowski, M.P., Costa, A.S.H., Higgins, M., Hams, E., et al. (2018). Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1. Nature *556*, 113–117.

Mulderrig, L., Garaycoechea, J.I., Tuong, Z.K., Millington, C.L., Dingler, F.A., Ferdinand, J.R., Gaul, L., Tadross, J.A., Arends, M.J., O'Rahilly, S., et al. (2021). Aldehyde-driven transcriptional stress triggers an anorexic DNA damage response. Nature *600*, 158–163.

Mullican, S.E., Lin-Schmidt, X., Chin, C.N., Chavez, J.A., Furman, J.L., Armstrong, A.A., Beck, S.C., South, V.J., Dinh, T.Q., Cash-Mason, T.D., et al. (2017). GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. *23*, 1150–1157.

Nagashima, R., Kosai, H., Masuo, M., Izumiyama, K., Noshikawaji, T., Morimoto, M., Kumaki, S., Miyazaki, Y., Motohashi, H., Yamamoto, M., and Tanaka, N. (2019). Nrf2 suppresses allergic lung inflammation by attenuating the type 2 innate lymphoid cell response. J. Immunol. *202*, 1331–1339.

Ogawa, T., Ishitsuka, Y., Nakamura, Y., Kubota, N., Saito, A., Fujisawa, Y., Watanabe, R., Okiyama, N., Suga, Y., Roop, D.R., and Fujimoto, M. (2020). NRF2 augments epidermal antioxidant defenses and promotes atopy. J. Immunol. *205*, 907–914.

Ong, C.K., Lirk, P., Tan, C.H., and Seymour, R.A. (2007). An evidence-based update on nonsteroidal anti-inflammatory drugs. Clin. Med. Res. *5*, 19–34.

Patel, S., Alvarez-Guaita, A., Melvin, A., Rimmington, D., Dattilo, A., Miedzybrodzka, E.L., Cimino, I., Maurin, A.C., Roberts, G.P., Meek, C.L., et al. (2019). GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. *29*, 707–718.e8.

Rangasamy, T., Guo, J., Mitzner, W.A., Roman, J., Singh, A., Fryer, A.D., Yamamoto, M., Kensler, T.W., Tuder, R.M., Georas, S.N., and Biswal, S. (2005). Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J. Exp. Med. *202*, 47–59.

Ratnam, N.M., Peterson, J.M., Talbert, E.E., Ladner, K.J., Rajasekera, P.V., Schmidt, C.R., Dillhoff, M.E., Swanson, B.J., Haverick, E., Kladney, R.D., et al. (2017). NF-κB regulates GDF-15 to suppress macrophage surveillance during early tumor development. J. Clin. Invest. *127*, 3796–3809.

Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., and Cuadrado, A. (2019). Activators and inhibitors of NRF2: a review of their potential for clinical development. Oxid. Med. Cell. Longev. *2019*, 9372182.

Rojo de la Vega, M., Chapman, E., and Zhang, D.D. (2018). NRF2 and the hallmarks of cancer. Cancer Cell *34*, 21–43.

Rollason, V., Samer, C.F., Daali, Y., and Desmeules, J.A. (2014). Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti-inflammatory drugs: a review. Curr. Drug Metab. *15*, 326–343.

Saito, R., Suzuki, T., Hiramoto, K., Asami, S., Naganuma, E., Suda, H., Iso, T., Yamamoto, H., Morita, M., Baird, L., et al. (2016). Characterizations of three major cysteine sensors of Keap1 in stress response. Mol. Cell. Biol. *36*, 271–284.

Santos, I., Colaço, H.G., Neves-Costa, A., Seixas, E., Velho, T.R., Pedroso, D., Barros, A., Martins, R., Carvalho, N., Payen, D., et al. (2020). CXCL5-mediated recruitment of neutrophils into the peritoneal cavity of Gdf15-deficient mice protects against abdominal sepsis. Proc. Natl. Acad. Sci. USA *117*, 12281–12287.

Scannevin, R.H., Chollate, S., Jung, M.Y., Shackett, M., Patel, H., Bista, P., Zeng, W., Ryan, S., Yamamoto, M., Lukashev, M., and Rhodes, K.J. (2012). Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J. Pharmacol. Exp. Ther. *341*, 274–284.

Schjerning, A.M., McGettigan, P., and Gislason, G. (2020). Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat. Rev. Cardiol. *17*, 574–584.

Schmidt, A. (1934). Die Industrielle Chemie in ihrer Bedeutung im Weltbild und Erinnerungen an ihren Aufbau (De Greuter).

Schumacher, H.R., Jr. (2004). Management strategies for osteoarthritis, ankylosing spondylitis, and gouty arthritis. J. Clin. Rheumatol. *10*, S18–S25.

Shen, T.Y., Windholz, T.B., Rosegay, A., Witzel, B.E., Wilson, A.N., Willett, J.D., Holtz, W.J., Ellis, R.L., Matzuk, A.R., Lucas, S., et al. (1963). Non-steroid anti-inflammatory agents. J. Am. Chem. Soc. *85*, 488–489.

Shi, J., Hua, L., Harmer, D., Li, P., and Ren, G. (2018). Cre driver mice targeting macrophages. Methods Mol. Biol. *1784*, 263–275.

Smith, C.E., Soti, S., Jones, T.A., Nakagawa, A., Xue, D., and Yin, H. (2017). Non-steroidal anti-inflammatory drugs are caspase inhibitors. Cell Chem. Biol. *24*, 281–292.

Sporn, M.B., and Liby, K.T. (2012). NRF2 and cancer: the good, the bad and the importance of context. Nat. Rev. Cancer *12*, 564–571.

Stone, E. (1763). An account of the succefs of the bark of the willow in the cure of agues. Philos. Trans. *53*, 195–200.

Suzuki, T., Gao, J., Ishigaki, Y., Kondo, K., Sawada, S., Izumi, T., Uno, K., Kaneko, K., Tsukita, S., Takahashi, K., et al. (2017). ER stress protein CHOP mediates insulin resistance by modulating adipose tissue macrophage polarity. Cell Rep. *18*, 2045–2057.

Takaya, K., Suzuki, T., Motohashi, H., Onodera, K., Satomi, S., Kensler, T.W., and Yamamoto, M. (2012). Validation of the multiple sensor mechanism of the Keap1-Nrf2 system. Free Radic. Biol. Med. *53*, 817–827.

Toth, R.K., and Warfel, N.A. (2017). Strange bedfellows: nuclear factor, erythroid 2-like 2 (Nrf2) and hypoxia-inducible factor 1 (HIF-1) in tumor hypoxia. Antioxidants (Basel) *6*, 27.

Trelle, S., Reichenbach, S., Wandel, S., Hildebrand, P., Tschannen, B., Villiger, P.M., Egger, M., and Jüni, P. (2011). Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ *342*, c7086.

Vane, J.R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. *231*, 232–235.

Venugopal, R., and Jaiswal, A.K. (1996). Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. Proc. Natl. Acad. Sci. USA *93*, 14960–14965.

Warner, T.D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J.A., and Vane, J.R. (1999). Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. USA *96*, 7563–7568.

Weng, J.H., Koch, P.D., Luan, H.H., Tu, H.C., Shimada, K., Ngan, I., Ventura, R., Jiang, R., and Mitchison, T.J. (2021). Colchicine acts selectively in the liver to induce hepatokines that inhibit myeloid cell activation. Nat. Metab. *3*, 513–522.

Winter, C.A., Risley, E.A., and Nuss, G.W. (1962). Carrageenin-induced edema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med. *111*, 544–547.

Winter, C.A., Risley, E.A., and Nuss, G.W. (1963). Anti-inflammatory and anti-pyretic activities of indomethacin, 1-(P-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid. J. Pharmacol. Exp. Ther. *141*, 369–376.

Wu, W., Peng, G., Yang, F., Zhang, Y., Mu, Z., and Han, X. (2019). Sulforaphane has a therapeutic effect in an atopic dermatitis murine model and activates the Nrf2/HO-1 axis. Mol. Med. Rep. *20*, 1761–1771.

Yamamoto, M., Kensler, T.W., and Motohashi, H. (2018). The KEAP1-NRF2 system: a thiol-based sensor-effector apparatus for maintaining redox homeo-stasis. Physiol. Rev. *98*, 1169–1203.

Zelenay, S., van der Veen, A.G., Böttcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A., et al. (2015). Cyclooxygenase-dependent tumor growth through evasion of immu-nity. Cell *162*, 1257–1270.

Zhang, Y., Talalay, P., Cho, C.G., and Posner, G.H. (1992). A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc. Natl. Acad. Sci. USA *89*, 2399–2403.

Zhou, S., Chan, E., Duan, W., Huang, M., and Chen, Y.Z. (2005). Drug bio-activation, covalent binding to target proteins and toxicity relevance. Drug Metab. Rev. *37*, 41–213.

Immunity
Article

 CellPress

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit anti-COX1	Cell signaling technologies	Cat#4841S
Rabbit GAPDH	Cell signaling technologies	Cat#2118S
Anti-Nrf2	Abcam	Cat#ab31163; RRID: AB_881705
IL1ß capture	Invitrogen	Cat#14-7012-85
IL1ß detection	eBioscience	Cat#13-7112-85: RRID: AB_466925
HRP-conjugated streptavidin	BD Pharmingen	Cat#554066: RRID: AB_2868972
CD45-PE	eBioscience	Cat#12-0451-83: RRID: AB_465669
CD45-APC	eBioscience	Cat#47-0451-82: RRID: AB_1548781
CD11b-Pacific Blue	Biolegend	Cat#101224: RRID: AB_755986
CD3-Alexa 700	eBioscience	Cat#56-0032-82: RRID:AB_529507
Ly6c-Brilliant Violet 605	Biolegend	Cat#128035: RRID: AB_2562352
Ly6g-GR1 FITC	eBioscience	Cat#11-5931-85; RRID: AB_465315
Ly6g-PECy7	BD Pharmingen	Cat#560601; RRID: AB_1727562
F4/80-APC	eBioscience	Cat#17-4801-82; RRID: AB_2784648
Anti-CD16/32(93) antibody	eBioscience	Cat#14-0161-86; RRID: AB_467135
Chemicals, peptides, and recombinant proteins		
indomethacin	Sigma-Aldrich	Cat#I7378
(S)-ibuprofen	Cayman Chemicals	Cat#16793
ketoprofen	Sigma-Aldrich	Cat#10006661
Etodolac	Cayman Chemicals	Cat#20833
naproxen	Cayman Chemicals	Cat#70290
rofecoxib	Cayman Chemicals	Cat#10010260
Sulforaphane	Cayman Chemical	Cat#10496
dimethylfumarate	Cayman Chemical	Cat#14714
LPS	Sigma-Aldrich	Cat#L2880
human M-CSF	Peprotech	Cat#AF-300-25
RNA Bee RNA isolation reagent	Tel-Test, Inc.	Cat#CS-501B
SMARTScribe Reverse Transcriptase	Takara	Cat#639538
PerfeCTa SYBR Green SuperMix	Quanta Biosciences	Cat#95054
Halt™ Protease Inhibitor Cocktail	ThermoFisher Scientific	Cat#78442
Collagenase IV	Worthington Biochemical Corporation	Cat#LS004188
Monosodium urate (MSU)	Invivogen	Cat#tlrl-msu
Critical commercial assays		
Pan Monocyte Isolation Kit, human	Miltenyi Biotec	Cat#130-096-537
H2DCFDA (ROS indicator)	ThermoFisher	Cat#D399
LDH Cytotoxicity Assay Kit	Cayman Chemical	Cat#601170
RNeasy Mini Kit	Qiagen	Cat#74106
Mouse/Rat GDF15 Quantikine ELISA Kit	R&D systems	Cat#MGD150
Mouse Cardiac Troponin I ELISA	Life Diagnostics	Cat#CTNI-1-HSP
Alanine Transaminase Colorimetric Activity Assay Kit	Cayman Chemical	Cat#700260
Micro BCA Protein Assay kit	ThermoFisher	Cat#23235
Pierce™ BCA Protein Assay Kit	ThermoFisher	Cat#23225
MinElute PCR Purification Kit	Qiagen	Cat#1026476

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Experimental models: Cell lines		
Human: Monocyte derived macrophages from human peripheral blood mononuclear cells		N/A
Mouse: Bone Marrow Derived Macrophages from various strains of mouse	Wang Lab	N/A
Experimental models: Organisms/strains		
Mouse: C57BL/6J (B6)	The Jackson Laboratory and bred in house	JAX: 000664
Mouse: B6.129X1-Nfe2l2^{tm1Ywk}/J (NRF2 KO)	The Jackson Laboratory	JAX: 017009
Mouse: B6.129S(Cg)-Ddit3$^{tm2.1Dron}$/J (CHOP KO)	The Jackson Laboratory	JAX: 005530
Mouse: B6.129P2-Lyz2$^{tm1(cre)Ifo}$/J (Lyz2 Cre)	The Jackson Laboratory	JAX: 004781
Mouse: C57BL/6-Nfe2l2$^{tm1.1Sred}$/SbisJ (Nrf2^{flox})	The Jackson Laboratory	JAX: 025433
Mouse: B6;129S4-Ptgs1tm1.1Hahe/J (Cox-1^{flox})	The Jackson Laboratory	JAX: 030884
Mouse: B6;129S4-Ptgs2tm1Hahe/J (Cox-2^{flox})	The Jackson Laboratory	JAX: 030785
Mouse: B6.129P2(SJL)-Myd88$^{tm1.1Defr}$/J (Myd88$^{-/-}$)	The Jackson Laboratory	JAX: 009088
Mouse: Eif2a$^{-/-}$	Dr. Anton Komar	N/A
Mouse: Nrf2 f/f ^{Lyz2}	This paper	N/A
Mouse: Cox1/2 f/f^{Lyz2}	This paper	N/A
Mouse: B6.BD-Keap1<em1(C151S)Mym>	RIKEN	RBRC09596
Oligonucleotides		
Gdf15	5'-CCGAGAGGACTCGAACTCAG-3'	5'-GGTTGACGCGGAGTAGCAG-3'
Tnf	5'-TCTGTCTACTGAACTTCGGGGTG-3'	5'-ACTTGGTGGTTTGCTACGACG-3'
Nrf2	5'- CTGAACTCCTGGACGGGACTA-3'	5'-CGGTGGGTCTCCGTAAATGG-3'
Ptgs1	5'-GTCCTGCTCGCAGATCCT-3'	5'-GTAGTTGTCGAGGCCAAAGC-3'
Ptgs2	5-GACCTGGGTTCACCCGAGGACTG-3'	5'-CCAAAGACTTCCTGCCCCACAGC-3'
Il1b	5'-CAGTTGTCTAATGGGAACGTCA-3'	5'-GCACCTTCTTTTCCTTCATCTTT-3'
Nqo1	5'-TCCAGACGTTTCTTCCATCC-3'	5'-GGTAGCGGCTCCATGTACTC-3'
Hmox1	5'-CATCCAAGCCGAGAATGCTG-3'	5'-CCTCAGGGAAGTAGAGTGGGG-3'
Cat	5'-TCCATCCAGCGTTGATTACA-3'	5'-ATCCAGGCTCTTCTGGACAA-3'
Gsr	5'-ACCACGAGGAAGACGAAATG-3'	5'-CCTGCAGCATCTCATCACAG-3'
Gclm	5'-TGGAGCAGCTGTATCAGTGG-3'	5'-TTGTTTAGCAAAGGCAGTCAAA-3'
Taldo1	5'-GCAAGGACAGAATTCTCATCAA-3'	5'-CAGTGTCATGTTGCAGTGGA-3'
Cxcl10	5'-AATGAAAGCGTTTAGCCAAAAA-3'	5'-GAGGCTCTCTGCTGTCCATC-3'
IL12a	5'-CTAGACAAGGGCATGCTGGT-3'	5'-TCTCCCACAGGAGGTTTCTG-3'
IL12b	5'-GGTGTAACCAGAAAGGTGCG-3'	5'-AAGGTGTCATGATGAACTTAG-3'
Il17a	5'-AAAGCTCAGCGTGTCCAAAC-3'	5'-AGCTTCCCAGATCACAGAGG-3'
Cxcl2	5'-AGTTTGCCTTGACCCTGAAGC-3'	5'-AGGCTCCTCCTTTCCAGG-3'
Ifng	5'-CGGCACAGTCATTGAAAGCCTA-3'	5'-GTTGCTGATGGCCTGATTGTC-3'
Gpr109a	5'-ATGGCGAGGCATATCTGTGTAGCA-3'	5'-TCCTGCCTGAGCAGAACAAGATGA-3'
Il6	5'-GACTTCCATCCAGTTGCCTTCTTGG-3'	5'-CCAGTTTGGTAGCATCCATCATTTCT-3'
Ifnb	5'-CCTGCAACCACCACTCATTC-3'	5'-GTCCTCAACTGCTCTCCACT-3'
GDF15	ThermoFisher Scientific	Hs00171132_m1
RPL13A	ThermoFisher Scientific	Hs04194366_g1

RESOURCE AVAILABILITY

Lead contact

Further information and requests for reagents may be directed to, and will be fulfilled by the lead contact Andrew Wang (andrew.wang@yale.edu).

Materials availability

Mouse lines generated in this study are available upon request from lead contact.

Data and code availability

This study did not generate or analyze datasets or code.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mice

All animal experiments were performed in accordance with institutional regulations after protocol review and approval by Yale University's Institutional Animal Care and Use Committee. C57BL/6J (B6), B6.129X1-Nfe2l2^{tm1Ywk}/J ($Nrf2^{-/-}$), B6.129S(Cg)-Ddit3$^{tm2.1Dron}$/J ($Chop^{-/-}$), B6.129P2-Lyz2$^{tm1(cre)Ifo}$/J ($Lyz2$ Cre), C57BL/6-Nfe2l2$^{tm1.1Sred}$/SbisJ ($Nrf2^{flox}$), B6;129S4-Ptgs1tm1.1Hahe/J ($Ptgs1^{flox}$), and B6;129S4-Ptgs2tm1Hahe/J ($Ptgs2^{flox}$) were obtained from Jackson Laboratory. Dr. Anton Komar provided bone marrow from $Eif2a$ deficient animals. Dr. Masayuki Yamamoto provided the $Keap1$ C151S transgenic animals. Dr. Andy MacMahon provided the $Gdf15$ deficient mice. Animals were used between the ages of 8 and 10 weeks. All mice were maintained in specific pathogen-free facility and all animal experiments were performed according to institutional regulations after protocol review and approved by Yale University's Institutional Animal Care and Use Committee.

Cell culture

Bone marrow derived macrophages (BMDMs) were prepared as previously described (Colegio et al., 2014). For assaying $Gdf15$ expression in response to various stimuli, BMDMs were plated in either 48 well or 24 well plates at a density of 2.5×10^5 or 5×10^5 per well, respectively.

Human monocyte-derived macrophages (MDMs) were derived from human peripheral blood mononuclear cells (PBMCs). Initially, monocytes were isolated from cryopreserved PBMCs as per protocol from a human monocyte isolation kit (130-096-537, Miltenyi Biotec). Monocytes were then cultured at 2.5E6/ml in X-VIVO 15 serum-free hematopoietic cell medium (Lonza) supplemented with 50 ng/ml of human M-CSF (AF-300-25, Peprotech) for five days. Cells were then re-plated prior to cell treatments.

METHOD DETAILS

Cell stimulation

BMDMs were treated with with 0.125 – 0.5 mM indomethacin (Sigma-Aldrich), 0.25 - 1 mM (S)-ibuprofen (Cayman Chemical), 0.125 – 0.5 mM ketoprofen (Sigma-Aldrich), 0.25 - 1 mM Etodolac (Cayman Chemical), or 0.25 - 1 mM naproxen (Cayman Chemical), 0.25-1 mM rofecoxib, 5 mM sulforaphane (Cayman Chemical), 100 μM dimethylfumarate. NSAIDs were diluted in 1% DMSO. Cells were pretreated with NSAID for 1 hour prior to stimulation with 10 ng/mL LPS (L2880, Sigma-Aldrich). LDH assay performed according to manufacturer's instructions (601170, Cayman Chemical). Reactive oxygen species (ROS) measured using H2DCFDA (D399, ThermoFisher) as described previously (Kavian et al., 2018). Sodium arsenite (Sigma-Aldrich), naphthalenedione (DMNQ, Cayman Chemical) and phenazine methosulfate (PMS, Cayman Chemical) at the indicated doses were used to induce ROS in BMDM.

MDMs were treated with indicated concentrations of indomethacin (Sigma-Aldrich), ketoprofen (Cayman Chemical), or sulforaphane (Cayman Chemical) for indicated durations.

RNA extraction and quantification

Cells were lysed in RLT lysis buffer according to manufacturer's instructions (QIAGEN). For tissue RNA extraction, tissues were excised into RNA Bee RNA isolation reagent (Tel-Test, Inc.) and disrupted by bead homogenization (Omni, Inc.). RNA was extracted using the RNeasy Kit according to manufacturer's instructions (QIAGEN). cDNA synthesis was performed using SMARTScribe Reverse Transcriptase (Takara) with oligo(dT) primers. qRT-PCR reactions were performed on either aCFX96 Real-Time System or CFX384 Real-Time System (Bio-Rad) using PerfeCTa SYBR Green SuperMix (Quanta Biosciences) or TaqMan assays, where indicated. Transcript levels were normalized to $Rpl13a$ or RPL13A.

Cytokine and tissue injury marker analysis

Whole blood was harvested from mice by retro-orbital bleeding and plasma was isolated using lithium heparin coated plasma separator tubes (365985, BD Pharmingen). Plasma GDF15 was quantified using a solid phase sandwich ELISA according to manufacturer's instructions (MGD150, R&D systems). Plasma IL-1ß was quantified by sandwich ELISA utilizing anti-mouse IL-1ß capture antibody (14-7012-85, Invitrogen), biotinylated rat anti-mouse IL-1ß detection antibody (13-7112-85, eBioscience), HRP-conjugated

streptavidin (554066, BD Pharmingen). Plasma Tropinin-I concentration and Alanine Aminotransferase (ALT) activity were assayed using kits according to manufacturers' protocols (Life Diagnostics and Cayman Chemical, respectively). Plasma creatinine and BUN were assayed using HPLC by The George M. O'Brien Kidney Center at Yale. Mouse multiplex cytokine/chemokine array 31-plex of serum cytokines from B6 and *Nrf2*$^{-/-}$ mice following intraperitoneal injection of LPS and vehicle or indomethacin was measured by Eve Technologies.

Immunofluorescence
BMDMs were treated for 4 hours with 0.5 mM Indomethacin (Sigma-Aldrich) then fixed with 4% PFA (Electron Microscopy Sciences) for 10 minutes at room temperature. Cells were then washed 3 times in ice-cold PBS, permeabilized with 0.25% Triton-X in PBS for 10 minutes at room temperature. After an additional 3 washes, cells were incubated in blocking buffer (1% BSA, 22.52 mg/mL glycine in PBST) for 30 minutes at room temperature. Cells were then incubated with primary antibody overnight at 4°C in 1% BSA in PBST. Cells were washed 3 times with PBS then incubated with secondary antibody in 1% BSA in PBST for 1 hour at room temperature. Cultures were washed again in PBS before counter staining with 0.1 μg/mL DAPI. After a final wash cells were imaged.

ChIP quantitative PCR
BMDMs were plated in 15 cm plates at a concentration of 1.5×10^7 cells per plate. Cells were stimulated with either 0.5 mM Indomethacin or vehicle control (1% DMSO) for 4 hours then fixed in 1% formaldehyde (Electron Microscopy Sciences) for 5 minutes at room temperature with gentle agitation. Post fixation, cells were quenched in 0.125M glycine for 5 minutes at room temperature under gentle agitation. Cells were then washed twice with ice cold PBS, scraped into pellets. Pellets were lysed with nuclear lysis buffer (50 mM Tris HCL, 10 mM EDTA, 0.8% SDS) with Halt™ Protease Inhibitor Cocktail (Sigma-Aldrich) for 15 minutes on ice. Samples were then spun at 11,000 RCF for 20 minutes to precipitate SDS. Protein levels were quantified using a Micro BCA Protein Assay kit (23235, ThermoFisher) and diluted with ChIP dilution buffer (16.7 mM TrisHCl (pH 8.0), 167 mM NaCl, 1.2 mM EDTA, 0.01% SDS, 1.1% Triton X-100) to 100 ug for anti-NRF2 (abcam31163, Abcam) antibody and 25 ug for anti-H3K27Ac antibody (ab4729, Abcam). Precipitation antibody were added to each sample then rotated overnight at 4°C. Dynabeads™ Protein G (Thermofisher) were added to each sample, rotated at 4°C for 2 hours then washed twice in Low Salt Immune Complex Wash Buffer (0.1% SDS, 1% Triton X-100, mM EDTA, 20 mM Tris-HCl, pH 8.1, 140 mM NaCl), once in LiCl Wash Buffer (0.25M LiCl, 1% IGEPAL CA630, 1% deoxycholic acid (sodium salt), 1mM EDTA, 10mM Tris, pH 8.1), and once in TE buffer. After final wash, beads were suspended in 250 uL Nuclear lysis buffer with 20 μg/ml proteinase K (Sigma-Aldrich). All samples were incubated at 55°C for 2 hours and then 65°C overnight. DNA was purified with MinElute PCR Purification Kit (1026476, QIAGEN).

To identify potential NRF2 binding sites in GDF15 regulatory elements (Figure S3), the ARE consensus sequence was downloaded from JASPAR (Fornes et al., 2020) and queried 10kB upstream and downstream of the GDF15 TSS. Due to the palindromic nature of consensus sequences, the reverse compliment, compliment, and reverse sequence of the JASPAR consensus sequence were included in our search algorithm. Identified potential ARE binding sites were searched against enhancer signatures (H3K4me1 or H3K27Ac) based on ENCODE data from BMDMs. The top twenty putative binding sites were screened using quantitative PCR reactions, which were run on CFX384 Real-Time System (Bio-Rad), and percent input was defined as two to the power of the difference in Cq of input and experimental samples. NRF2 binding was then confirmed by designing primers spanning 1 kb upstream and downstream of the identified binding site to detect a peak of enrichment.

Western blot
BMDMs were lysed in Triton-X Lysis buffer (150 mM NaCl, 0.1% Trition-X, 50 mM Tris HCl) with Halt™ Protease Inhibitor Cocktail (Sigma-Aldrich) then centrifuged at 12,000 rpm for 20 minutes at 4°C. Protein concentration in cell lysates were quantified by Pierce™ BCA Protein Assay Kit (ThermoFisher). Sample volume equivalent to 20 μg were mixed with 4x Leammli buffer (Bio Rad) boiled at 95°C for 5 minutes then run on a 4–20% Mini-PROTEAN® TGX™ Precast Protein Gels (BioRad) in running buffer (25 mM Tris, 190 glycine, 0.1% SDS) using a Mini-PROTEAN Tetra Vertical Electrophoresis Cell (BioRad). Protein was then transferred to blotting membrane using a transfer cassette in transfer buffer (25 mM Tris, 190mM glycine, 20% methanol) for 1.5 hours at 100V. Blot was then blocked for 1 hour at room temperature with 5% milk in PBST, then incubated overnight in primary antibody diluted in 5% milk at 4°C. Blots were then washed 5 times in TBST, incubated in HRP conjugated secondary antibody for 1 hour at room temperature. Blots were imaged with a ChemiDoc Imaging System (17001401, BioRad).

Flow cytometry
For flow cytometry of CD45+ cells from the liver, mice were treated LPS and indomethacin or vehicle and then sacrificed 20 hours later. Livers were harvested, finely diced using a razor blade, and incubated in 2 mg/ml Collagenase IV (Worthington Biochemical Corporation) at 37°C under constant agitation for 30 minutes. The resultant suspension was then mechanically forced through a 70-micron cell strainer to generate a single cell suspension and washed prior to staining. Functional grade mouse anti-CD16/32 (93) antibody was used for Fc-block. At least 1×10^5 cells were acquired on CD45$^+$ cells within the singlet live gate, as defined by size, granularity and pulse-width. Samples were acquired on an LSRII flow cytometer (BD). Fcs files were analyzed using FlowJo (Tree Star Technologies).

Immunity
Article

ℰ **CellPress**

In vivo inflammatory mouse models

For acute response to bardoxolone, C57BL/6 mice were gavaged with vehicle (sesame oil) or bardoxolone methyl (Sigma-Aldrich SMB00376) at the indicated concentrations. For long-term bardoxolone feeding experiments, bardoxolone (Sigma-Aldrich SMB00376) was mixed into moist regular chow at 0.01% wt/wt and dried. This food was then fed to C57BL/6 mice for the indicated number of days. Indomethacin was dosed at 5-15 mg/kg, consistent with the long-standing dosing used in the rodent literature (Crestani et al., 1991; Liang et al., 2015; Winter et al., 1963), which is within linear range of dosing in humans (50 mg TID in a 50 kg adolescent would be 3 mg/kg/d).

For LPS endotoxemia, mice were injected intraperitoneally with sub-lethal doses of LPS derived from Escherichia coli 055:B5 (L2880, Sigma-Aldrich) diluted in PBS. Dosing varies dramatically from lot to lot. New lots are tested for LD50. In these studies, sub-lethal doses are 2.5 mg/kg. Mice were injected intraperitoneally with 5 mg/kg indomethacin or 5 mg/kg ketoprofen diluted in bicarbonate buffer, every 4 hours for the duration of the experiment, starting 15 minutes prior to LPS administration. Temperature was measured at regular intervals using a rectal probe. Mice were euthanized and organs harvested 20 hours later. Validation and dosing of GDF15 neutralizing antibody and recombinant GDF15 are previously described (Luan et al., 2019).

For the gout model, the hind foot pad was injected intradermally with saline (right hind foot) or MSU (left hind foot) (1 mg in 40 uL PBS, Invivogen). Mice were injected intraperitoneally with vehicle or 2.5 mg/kg indomethacin diluted in bicarbonate buffer twice daily. Calipers were used to measure diameter of the foot at baseline and 24 hours after injection.

QUANTIFICATION AND STATISTICAL ANALYSIS

Results were statistically analyzed using Student's *t* test or an analysis of variance (ANOVA) test with multiple comparisons where appropriate using Prism 6.0 (GraphPad Software, Inc). p value of < 0.05 was considered to be statistically significant.